

Standard of Care Total Body Irradiation for Scleroderma: **Duke Institutional Implementation**

Duke University
School of Medicine

A. Rodrigues¹, Q. Wu¹, S. Meltsner¹, Y. Sheng¹, N. Larrier¹, O. Craciunescu¹ ¹Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710

PURPOSE

We present our institution's experience to assist other centers in starting up their own TBI for scleroderma program.

INTRODUCTION

Systemic Sclerosis/Scleroderma is an autoimmune disease with considerable morbidity and mortality. It causes excessive collagen production leading to thickening and tightening of skin as well as damage to internal organs such as kidneys and lungs. The estimated incidence rate is approximately 20 cases per million per year.

Recently, Total Body Irradiation (TBI) conditioning as part of an autologous hematopoietic stem-cell transplantation has become standard of care per the outcome of the randomized phase II study The Scleroderma: Cyclophosphamide (CY) or Transplantation (SCOT) Trial.

Prescription: 200 cGy x 4 fractions **Lung/Kidney Limits: 50 cGy x 4 fractions**

Our group's previous work as part of the SCOT trial has been previously published [1]. This includes kidney block design for improved dosimetry. TBI for scleroderma involves coordination between multiple departments and individuals making it a challenging technique in terms of physics as well as practical aspects.

These challenges have impeded its widespread implementation.

METHODS

Coordination with BMT Program

Challenges:


- Machine Scheduling for
- Simulation (CT, MV on Linac, US)
- Treatment
- Physics Department Coverage

Radiation Oncologist Consult


Challenges:

- Physics consulted if patient in poor condition e.g. difficulty bending arms
- Potential adjustment or modifications to TBI stand e.g. adjustment of handholds
- → The earlier these issues are addressed, the more efficiently the treatment can be simulated, planned, and delivered.

Patient dimensions measured







MV Chest



Ultrasound:

Challenges:


Radiograph for Establish kidney size & location CT:

- To ensure accurate positioning: Reference 3 BBs are placed on anterior and posterior patient surface at known distances; BB locations
- Supine Kidney positions contoured used as guide for US Kidney location/size

MV: Account for magnification from lung midline to imager US: Acquire both prone and sitting US to evaluate kidney size and potential shifts due to breathing or positional (change from prone, supine → sitting (treatment position)

TBI dose calculation using MU hand calculation

Commissioning Block transmission





Patient-specific block generation



- Physics determination of appropriate kidney block shape and location based on CT -> US variation
- Physician draws and approves lung/kidney blocks
- Planning: Block thickness determination
- Block generation time-consuming, training intensive process
- Physics physical inspection of blocks important: no air bubbles, cracks; enough room on block tray to adjust position of blocks

Delivery **Physics**


Therapists **Physicians**





Dry-run:

Initial set-up, Marking Block positions, CR verification




Treatment Fractions 1 – 4:


- Fx 1: OSLDs for Prescription point, lung, kidney
- AM fx 1 & 3: Based on Initial set-up and Block positions, CR verification
- PM fx 2 & 4: Based on initial setup and marked block positions

- Patient compliance strongly depends on patient's condition and support from staff in BMT program.
- 3rd fraction (2nd day AM), patient typically more exhausted due to ATG infusions and extensive monitoring
- Dry run time slot up to 2 hrs
- Treatment fraction time slots approximately 1-1.5 hrs

RESULTS

Sixteen patients from 8/2018 to 5/2020 were treated since TBI for Scleroderma became standard of care.





Lung and kidney dose had a **higher** variability.

CONCLUSIONS

With TBI conditioning pre-transplantation becoming the new standard of care for scleroderma, careful implementation of not just physics but also practical aspects can achieve satisfactory dosimetry.

REFERENCES

[1] Craciunescu, O. I. et al. (2011). Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial. International Journal of Radiation Oncology* Biology* Physics, 79(4)

CONTACT INFORMATION

oana.craciunescu@duke.edu